

> **The Company**

AmpliMed Corporation is dedicated to the rapid and efficient clinical development of oncology drugs that overcome challenges of toxicity, multi-drug resistance and cardiac toxicity that frequently limit the utility of cancer therapy.

> **Products**

Its lead product, AmpliMexion, has particular promise for the treatment of pancreatic cancer, malignant melanoma, lung cancer, and multiple myeloma. Other products in its portfolio (including Amplizone) have promise in ovarian, breast, prostate, and other common cancers. These compounds are being developed as new therapies to regress cancer and to prolong the patient survival.

AmpliMed compounds have novel ways of killing cancer cells, which are distinct from many other anticancer drugs. They may also avoid some of the toxicity, which is common in cancer drugs, and bypass the resistance mechanisms built up by the cancer cells. This gives its drugs significant potential advantages, enabling them to avoid some of the factors, which limit the use of many other cancer chemotherapeutics.

AmpliMed has won three "orphan drug" designations for AmpliMexion, giving it development and patent rights for specific uses for seven years. Used for the treatment of melanoma (deadliest form of skin cancer), pancreatic cancer, and bone marrow cancer, AmpliMed's compounds avoid side effects while overcoming multidrug resistance, which often defeats current chemotherapy. AmpliMed has 30 patented derivatives of its main product.

> **Management Team**

AmpliMed was founded by an experienced team of senior faculty members at AZ Cancer Center.

ROBERT A. ASHLEY, Chairman, CEO and President, most recently was Senior Vice President, Commercial Development of a US public company. He has over 24 years experience in managing complex clinical development and regulatory strategies, and was central in building a 160-person, \$50 million sales, \$200 million market cap entity from start-up. He also an additional 15 years experience in leadership roles in several large and small pharmaceutical companies.

The company founders, DR. EVAN HERSH, Vice President Clinical Affairs and Chief Medical Officer, and DR. DAVID ALBERTS, Vice President Business Development, oncologists at the Arizona Cancer Center (AZCC). Both are former members of ODAC, the FDA's Oncology Drug Advisory Committee. Both have in-depth experience with oncology patients and have directed and participated in many oncology drug trials. They have consulted widely for the pharmaceutical industry. They have also participated in the founding and management of successful biotechnology companies. Because of the way the company is structured it has excellent access to important scientific resources.

> **Opportunity**

Markets for effective products with minimal or no side effects are large and growing. Total worldwide sales of oncology drugs exceeded \$13 billion in 2003, with the top 200 products accounting for greater than \$11 billion. Several chemotherapy drugs have attained blockbuster status (\$1 billion or more per year revenues). The gross margins on these drugs are 80-90%, typical of the pharmaceutical industry. AmpliMed's anticancer drugs exhibit novel mechanisms of action designed to overcome some of the limitations and toxicities associated with some current cancer therapy. They are safe products that are cost effective and have broad applicability. The review and approval of such cancer drugs can often be fast-tracked by the regulatory authorities.

In addition to AmpliMexion, Amplimed has a portfolio of compounds, some related, some with other unique mechanisms and characteristics that have the potential to overcome many of the toxicity and resistance limitations of current chemotherapies.

AmpliMexion's portfolio of drugs includes more than 180 unique compounds that have exhibited the potential to avoid some of the common toxicities of current anticancer drugs and overcome multi-drug resistance, which often defeats current cancer chemotherapy.

The financial markets are risky. Investing is risky. Past performance does not guarantee future performance. The foregoing has been prepared solely for informational purposes and is not a solicitation, or an offer to buy or sell any security. Offering made by Offering Memorandum only. Opinions are based on historical research and data believed reliable, but there is no guarantee that future results will be profitable. This does not purport to be a complete analysis of the Portfolio Company. The author has relied on information provided by sources deemed to be reputable and although believed to be true, cannot guarantee the accuracy of such information. All claims made by this brochure should be verified by the reader. This brochure is not intended to directly or indirectly provide advice as to the value of any offer described herein, or as to the advisability of investing in such offer. Investing is not suitable for everyone; you should know and understand the risk before making a decision.